PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsAOP Health
AOP Health
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
BesremiRopeginterferon alfa-2b2019-02-15
Polycythemia vera
Sugammadex amomedSugammadex2023-01-102026
Neuromuscular blockade
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Ropeginterferon alfa-2b
chronic hepatitis
,
healthy volunteers/patients
,
t-cell lymphoma cutaneous
,
neoplasms
,
hepatitis
,
hepatitis a
,
thrombocytosis
,
hepatitis d
,
coinfection
,
hepatocellular carcinoma
,
liver neoplasms
,
myelomonocytic leukemia chronic
,
leukemia myeloid chronic atypical bcr-abl negative
,
myelodysplastic-myeloproliferative diseases
,
polycythemia
,
chronic hepatitis b
,
hepatitis c
,
chronic hepatitis c
,
essential thrombocythemia
,
primary myelofibrosis
,
infections
,
communicable diseases
,
polycythemia vera
,
myeloproliferative disorders
,
hepatitis b
,
herpesviridae infections
Landiolol
healthy volunteers/patients
,
coronary disease
,
pharmacokinetics
,
heart arrest
,
out-of-hospital cardiac arrest
,
tachycardia
,
coronary artery disease
,
septic shock
,
supraventricular tachycardia
,
shock
,
postoperative complications
,
atrial fibrillation
,
myocardial ischemia
,
cardiac surgical procedures
,
heart failure
,
low cardiac output
,
heart disease risk factors
,
primary dysautonomias
,
left ventricular dysfunction
,
ventricular dysfunction
,
st elevation myocardial infarction
Benzocaine
amyotrophic lateral sclerosis
,
falciparum malaria
,
relapsing-remitting multiple sclerosis
,
malaria
,
leukemia
,
myelodysplastic syndromes
,
hematologic neoplasms
,
lymphoma
,
graft vs host disease
,
cough
,
aplastic anemia
,
venous thromboembolism
,
thromboembolism
,
healthy volunteers/patients
,
hip fractures
,
myocardial infarction
,
st elevation myocardial infarction
,
infarction
,
glucose intolerance
,
pharyngitis
,
dengue
,
severe dengue
,
viral hemorrhagic fevers
,
hygiene
,
autonomic nervous system diseases
,
immune system diseases
,
skin diseases
,
eczematous skin diseases
,
hypersensitivity
,
immediate hypersensitivity
,
type 2 diabetes mellitus
,
atopic dermatitis
,
eczema
,
dermatitis
,
acute coronary syndrome
,
kidney diseases
,
chronic kidney failure
Tezosentan
reperfusion injury
,
delayed graft function
,
persistent fetal circulation syndrome
,
systemic scleroderma
,
localized scleroderma
,
diffuse scleroderma
,
vascular diseases
,
cardiovascular diseases
,
respiratory tract diseases
,
connective tissue diseases
,
lung diseases
,
liver transplantation
,
hypertension
,
pulmonary arterial hypertension
,
pulmonary hypertension
,
familial primary pulmonary hypertension
,
respiratory aspiration
,
congenital heart defects
,
heart diseases
Alfacalcidol
dermatomyositis
,
ulcerative colitis
,
hyperparathyroidism
,
secondary hyperparathyroidism
,
neoplasm metastasis
,
chronic renal insufficiency
,
left ventricular hypertrophy
,
kidney diseases
,
cardiomegaly
,
hypertrophy
Albinterferon alfa-2b
hepatitis a
,
leukemia
,
myeloid leukemia
,
hepatitis b
,
chronic hepatitis b
,
bcr-abl positive chronic myelogenous leukemia
,
hepatitis
,
chronic hepatitis
,
hepatitis c
,
chronic hepatitis c
,
polycythemia vera
,
myeloid leukemia chronic-phase
LANCOVUTIDE
healthy volunteers/patients
,
fibrosis
,
cystic fibrosis
Nepidermin
hereditary angioedemas
,
angioedema
Retinol
neoplasms
,
cancer pain
,
melanoma
,
oncogenes
,
bacterial infections
,
atrial fibrillation
,
osteoporosis
,
pancreatic neoplasms
,
psoriasis
,
respiratory tract infections
,
infections
,
acne vulgaris
,
bone fractures
,
malaria
,
yellow fever
,
rubella
,
type 2 diabetes mellitus
Ldla202
healthy volunteers/patients
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use